{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:20:23Z","timestamp":1745554823720,"version":"3.40.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,24]]},"DOI":"10.7759\/cureus.82907","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T14:30:43Z","timestamp":1745505043000},"source":"Crossref","is-referenced-by-count":0,"title":["Mucosal-Dominant Stevens-Johnson Syndrome Presenting as Hemorrhagic Glossitis in a Multimorbid Patient: A Diagnostic Challenge"],"prefix":"10.7759","author":[{"given":"Bhavik R","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau JC","year":"1994","unstructured":"Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994, 331:1272-85. 10.1056\/NEJM199411103311906","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt M","year":"2011","unstructured":"Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011, 7:803-15. 10.1586\/eci.11.66","journal-title":"Expert Rev Clin Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch M","year":"2018","unstructured":"Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018, 54:147-76. 10.1007\/s12016-017-8654-z","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-3322","article-title":"Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children","volume":"128","author":"Finkelstein Y","year":"2011","unstructured":"Finkelstein Y, Soon GS, Acuna P, et al.. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011, 128:723-8. 10.1542\/peds.2010-3322","journal-title":"Pediatrics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14404","article-title":"Reactive infectious mucocutaneous eruption: Mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions","volume":"46","author":"Ramien ML","year":"2021","unstructured":"Ramien ML. Reactive infectious mucocutaneous eruption: Mycoplasma pneumoniae-induced rash and mucositis and other parainfectious eruptions. Clin Exp Dermatol. 2021, 46:420-9. 10.1111\/ced.14404","journal-title":"Clin Exp Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell PB Jr","year":"2008","unstructured":"Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008, 9:1543-6. 10.2217\/14622416.9.10.1543","journal-title":"Pharmacogenomics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr T","year":"2010","unstructured":"Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010, 5:39. 10.1186\/1750-1172-5-39","journal-title":"Orphanet J Rare Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2019.05.050","article-title":"Critical analysis and limitations of resting ankle-brachial index in the diagnosis of symptomatic peripheral arterial disease patients and the role of diabetes mellitus and chronic kidney disease","volume":"71","author":"AbuRahma AF","year":"2020","unstructured":"AbuRahma AF, Adams E, AbuRahma J, Mata LA, Dean LS, Caron C, Sloan J. Critical analysis and limitations of resting ankle-brachial index in the diagnosis of symptomatic peripheral arterial disease patients and the role of diabetes mellitus and chronic kidney disease. J Vasc Surg. 2020, 71:937-45. 10.1016\/j.jvs.2019.05.050","journal-title":"J Vasc Surg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas B","year":"2010","unstructured":"Sassolas B, Haddad C, Mockenhaupt M, et al.. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010, 88:60-8. 10.1038\/clpt.2009.252","journal-title":"Clin Pharmacol Ther"},{"key":"ref10","unstructured":"Wikimedia Commons. Mucosal desquamation in a person with Stevens-Johnson syndrome.jpg. (2011). Accessed: April 14, 2025: https:\/\/commons.wikimedia.org\/wiki\/File:Mucosal_desquamation_in_a_person_with_Stevens%E2%80%93Johnson_syndrome.jpg."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"153","author":"Zimmermann S","year":"2017","unstructured":"Zimmermann S, Sekula P, Venhoff M, et al.. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis. JAMA Dermatol. 2017, 153:514-22. 10.1001\/jamadermatol.2016.5668","journal-title":"JAMA Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092105","article-title":"A review of the systemic treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"10","author":"Chang HC","year":"2022","unstructured":"Chang HC, Wang TJ, Lin MH, Chen TJ. A review of the systemic treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. Biomedicines. 2022, 10:10.3390\/biomedicines10092105","journal-title":"Biomedicines"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/362643-mucosal-dominant-stevens-johnson-syndrome-presenting-as-hemorrhagic-glossitis-in-a-multimorbid-patient-a-diagnostic-challenge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T14:30:43Z","timestamp":1745505043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/362643-mucosal-dominant-stevens-johnson-syndrome-presenting-as-hemorrhagic-glossitis-in-a-multimorbid-patient-a-diagnostic-challenge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.82907","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}